Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Coherus Oncology, Inc. (NASDAQ:CHRS) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.95 and traded as high as $1.54. Coherus Oncology shares last traded at $1.53, with a volume of 3,059,639 shares traded.

Wall Street Analyst Weigh In

Separately, Maxim Group raised Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Thursday, September 4th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $4.51.

Coherus Oncology Trading Up 13.3%

The firm has a market capitalization of $177.83 million, a price-to-earnings ratio of 0.99 and a beta of 0.88. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.44 and a quick ratio of 1.43. The firm’s 50-day simple moving average is $1.08 and its 200 day simple moving average is $0.95.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC acquired a new position in shares of Coherus Oncology during the second quarter worth $33,000. CWM LLC increased its holdings in shares of Coherus Oncology by 96.6% during the first quarter. CWM LLC now owns 49,793 shares of the biotechnology company’s stock worth $40,000 after buying an additional 24,468 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Coherus Oncology by 97.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company’s stock worth $43,000 after buying an additional 15,214 shares in the last quarter. Cerity Partners LLC increased its holdings in shares of Coherus Oncology by 84.0% during the first quarter. Cerity Partners LLC now owns 54,676 shares of the biotechnology company’s stock worth $44,000 after buying an additional 24,953 shares in the last quarter. Finally, Corient Private Wealth LLC increased its holdings in shares of Coherus Oncology by 20.0% during the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after buying an additional 10,000 shares in the last quarter. 72.82% of the stock is currently owned by institutional investors and hedge funds.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.